Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.22 USD | -0.82% | -4.58% | -13.80% |
May. 03 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
May. 02 | Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.80% | 3.42B | |
+2.97% | 108B | |
+10.21% | 104B | |
+1.57% | 22.33B | |
-12.77% | 22.19B | |
-7.05% | 18.69B | |
-37.64% | 17.74B | |
-6.50% | 17.64B | |
+6.00% | 14.05B | |
+37.20% | 12.51B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Baird Adjusts Price Target on Ultragenyx Pharmaceutical to $57 From $50, Maintains Outperform Rating